Mark Quick is an experienced professional in the life sciences and pharmaceuticals sectors, serving as Chairperson of the Board and Board Member at AnaCardio since September 2022. Currently, Mark Quick is a Partner at Flerie Invest, contributing to various biotech and pharma companies, and holds multiple board positions including A3P Biomedical, BOHUS, and Empros Pharma. Previously, Mark Quick had an extensive career at Recipharm, holding roles from Head of Mergers and Acquisitions to Executive Vice President of Corporate Development, and served as Head of Business Development at Celltech. Mark Quick's educational background includes an MBA from Open University Business School and a BSc (Hons) in Industrial Studies from Nottingham Trent University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices